Apoptotic-Regulatory and Complement-Protecting Protein Expression in Chronic Lymphocytic Leukemia: Relationship to In Vivo Rituximab Resistance
- 15 April 2003
- journal article
- hematologic malignancies
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 21 (8) , 1466-1471
- https://doi.org/10.1200/jco.2003.06.012
Abstract
Purpose: Rituximab has clinical activity in patients with chronic lymphocytic leukemia (CLL) and has a variety of proposed mechanisms, including apoptosis, complement-dependent cell lysis (CDC), an...Keywords
This publication has 32 references indexed in Scilit:
- Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)Blood, 2002
- The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein–kinase–dependent mechanismBlood, 2002
- The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis inductionBlood, 2002
- CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59Blood, 2001
- Rituximab therapy of patients with B-cell chronic lymphocytic leukemiaBlood, 2001
- Rituximab (Anti‐CD20) Therapy of B‐Cell Lymphomas: Direct Complement Killing is Superior to Cellular Effector MechanismsScandinavian Journal of Immunology, 2000
- Detection of Multiple Antigens on Western BlotsAnalytical Biochemistry, 1996
- Multiple Bcl-2 family members demonstrate selective dimerizations with Bax.Proceedings of the National Academy of Sciences, 1995
- Expression of protectin (CD59) in human melanoma and its functional role in cell‐ and complement‐mediated cytotoxicityInternational Journal of Cancer, 1995
- Expression of the complement regulatory proteins CD21, CD55 and CD59 on Burkitt lymphoma lines: their role in sensitivity to human serum‐mediated lysisEuropean Journal of Immunology, 1992